About the API
Venlafaxine hcl First introduced in 1993, venlafaxine was the sixth most widely used antidepressant in the US in 2007 (17.1 million, based on the amount of retail prescriptions).
The drug is indicated for the treatment of major depressive/bipolar mood disorders, and is an effective treatment for those diagnosed with anxiety disorders (general, social anxiety, panic disorder).
Venlafaxine is both structurally and pharmacologically unique to other antidepressants on the market for treatment of generalized anxiety disorders. It is often effective for depressive disorders where traditional SSRIs have no effect.
First disclosed in 1986 (Biochem. Pharmacol. 35(24): 4493; U.S. Pat. No. 4,609,758), generic formulations of venlafaxine have been available on the market since 2006.
Presently, venlafaxine hydrochloride is manufactured through efficient large-scale synthetic organic chemistry methods starting from simple, commercially available (petrochemical) precursors.